A Case Report of Immune Checkpoint Inhibitor-Associated Acute Pancreatitis Presenting as Mixed DKA/HHS: Histopathological and Radiological Findings

Amanda Sams

Follow this and additional works at: https://digitalcommons.providence.org/publications

Part of the Cardiology Commons, Medical Education Commons, and the Oncology Commons

Recommended Citation
https://digitalcommons.providence.org/publications/8090

This Presentation is brought to you for free and open access by Providence Digital Commons. It has been accepted for inclusion in Articles, Abstracts, and Reports by an authorized administrator of Providence Digital Commons. For more information, please contact digitalcommons@providence.org.
A Case Report of Immune Checkpoint Inhibitor-Associated Acute Pancreatitis Presenting as Mixed DKA/HHS: Histopathological and Radiological Findings

Amanda L. Sams, MD
Spokane Teaching Health Center Transitional Year Residency

Case Description

- 88 y/o M with history of CAD, atrial fibrillation on warfarin, and stage IV bladder cancer s/p TURBT 08/2022
- Initially presented with several days of worsening fatigue, confusion, irritability, lightheadedness, abdominal pain, back pain, loose stools, polydipsia
- Initial labs significant for: corrected Na 158, glucose 1086, bicarb 16, AG 23, K 6.5, Cr 1.4, lactate 2.5, venous pH 7.32, serum osmolality 351, small serum ketones, UA 3+ glucose and 2+ ketones, corrected Ca 13, ionized calcium 1.67
- Admitted to the ICU for management of DKA/HHS
- Met criteria for acute pancreatitis with epigastric/RUQ tenderness on exam and serum lipase 988
- LFTs and triglycerides within normal limits
- RUQ US: no gallstones, cholecystitis (fig. 1A), or CBD dilatation. Pancreas appeared grossly normal (fig. 1B).
- Family denied history of tobacco or alcohol use
- NPO, DKA protocol, aggressive IVF resuscitation
- Patient had been receiving pembrolizumab (PD-1 receptor antagonist) every 3 weeks outpatient over the past several months for his metastatic bladder cancer
- No history of DM; A1c had increased from 5.6% (07/29/2022) to 8.5% on admission (09/18/2022)
- Baseline CT A/P (04/2022): A few punctate calcifications within the pancreatic parenchyma suggestive of chronic pancreatitis. No peripancreatic inflammatory change or mass
- No additional CT scan was done during this hospitalization

Discussion

- With other common causes of pancreatitis ruled out and only a moderate hypercalcemia, pembrolizumab was believed to be the culprit of pancreatitis leading to DKA/HHS in this patient’s case
- Hirota et. al. (05/2022): Histopathological appearance of pembrolizumab-induced pancreatitis (fig. 3)
  - Neutrophil infiltration (seen in type 2 AIP)
  - Acinar-ductal metaplasia
  - Non-specific fibrosis
  - Fat deposition
    - No fat necrosis (seen in AP)
  - CD68+ T-cell infiltrates
    - No IgG4-positive plasma cells (seen in type 1 AIP)
    - No CD4+ T cells (seen in classic T1DM)

Discussion (continued)

- Pembrolizumab binds the PD-1 receptor on T-cells, preventing their inactivation by tumor cells
- Decreased T-cell regulation appears to lead to autoimmune-like pattern of pancreatic injury which may affect endocrine or exocrine function
- Immune checkpoint inhibitor (ICI)-associated pancreatitis is uncommon; <1% incidence of moderate to severe pancreatitis in most clinical trials
- ICI-associated pancreatitis is usually asymptomatic with incidentally discovered elevations in serum lipase
- Management involves holding the ICI in these cases
- In severe cases, steroids are recommended in addition to the standard IVF, pain control, bowel rest
- Typically 0.5–1 mg/kg/day prednisone/methylprednisolone with a 4-6 week taper. In severe cases, a double daily dose may be given
- Imaging findings related to ICI pancreatitis include pancreatic enlargement, decreased attenuation, and surrounding fat stranding. PET/CT may show increased FDG uptake
- ICIIs are also rarely associated with new T1DM with reported incidence of <0.5%
- Wide range in the time of onset: as early as a single cycle of ICI treatment. Average onset after 20 cycles of immunotherapy
- The majority of these patients presented with DKA

Conclusion

- This case is unusual in that the patient presented with a mixed DKA/HHS picture in addition to acute pancreatitis. Loose stools may indicate exocrine gland dysfunction, if so, this is a very unique presentation of both endocrine and exocrine pancreatic dysfunction caused by pembrolizumab
- Despite its rarity, clinicians should be aware of adverse effects of ICIIs including new onset DM (which often presents as DKA) and acute pancreatitis
- More research is needed to further characterize histopathology and determine optimal treatment guidelines

References

- Available upon request
• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517772/
• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000995/
• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959713/

• 418
• 7080